Sunvozertinib achieved a statistically significant, clinically meaningful PFS advantage over platinum-based chemotherapy by ...
The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...
The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient ...
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did not flag problems with the drug’s efficacy or safety.
According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...
Cemiplimab monotherapy offers quality-of-life benefits over chemotherapy in patients with advanced NSCLC and PD-L1 expression ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
A regimen based on Incyte's PD-1 inhibitor Zynyz and chemotherapy has become the first systemic treatment to be approved in the EU for advanced squamous cell carcinoma of the anal canal (SCAC). Zynyz ...
Novocure to launch Optune Lua in Japan with national reimbursement coverage Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for ...
Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in ...
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua ® through the country’s National Health Insurance coverage. Optune Lua ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR?)-targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results